Background: Acute eczematous facial dermatitis can cause erythema, edema, and severe pruritus, with marked effects on sleep and quality of life. Treatment during pregnancy is challenging because therapeutic options are limited by safety concerns. Case Presentation: This single case report describes a 35-year-old pregnant woman at 9 weeks’ gestation who presented with a 10-day history of progressive facial erythema, swelling, and severe pruritus. She had recurrent facial dermatitis, allergic rhinitis, and asthma, supporting an atopic background. Antihistamines and topical corticosteroids were ineffective. Acute eczematous facial dermatitis with atopic features was considered. After risk–benefit assessment and informed consent, stapokibart was initiated with a 600 mg loading dose followed by 300 mg on day 10. Results: Pruritus became minimal within 3 days after the first injection. By day 10, facial erythema and edema had markedly improved; by day 31, the lesions had nearly resolved. EASI decreased from 4.2 to 2 and 1 at day 10 and day 31, respectively; IGA improved from 4 to 2 and 0; pruritus NRS decreased from 8– 9 to 3– 4 and 0; and DLQI improved from 25 to 7 and 2. No treatment-related adverse events were reported during short-term follow-up. At the time of manuscript preparation, the pregnancy was ongoing at 18 weeks’ gestation, with normal prenatal ultrasonography and no reported obstetric complications. Conclusion: Stapokibart may provide rapid short-term improvement in selected patients with acute eczematous facial dermatitis with atopic features during pregnancy. During short-term follow-up to 18 weeks’ gestation, no treatment-related adverse events or obstetric complications were reported. However, no conclusions regarding maternal or fetal safety can be drawn from this single case, and continued follow-up is essential. Keywords: stapokibart, acute eczematous facial dermatitis, atopic dermatitis, pregnancy, biologic therapy
Zhu et al. (Fri,) studied this question.